Lyell Immunopharma, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2019 | 116.4% | 116.4% | — |
| FY2020 | 69.9% | 69.9% | -22.5% |
| FY2021 | -26.9% | -26.9% | -22.2% |
| FY2022 | -22.0% | -22.0% | -19.5% |
| FY2023 | -35.8% | -35.8% | -31.3% |
| FY2024 | -89.6% | -89.6% | -69.9% |
| FY2025 | -110.6% | -110.6% | -80.7% |